Update information
August 2024: Recommendation 1.1 was updated and partially replaced by NICE technology appraisal guidance on pembrolizumab with platinum- and fluoropyrimidine-based chemotherapy for untreated advanced HER2-negative gastric or gastro-oesophageal junction adenocarcinoma (TA997). This is because the marketing authorisation for pembrolizumab has been updated since this guidance was published, and it now has a marketing authorisation for locally advanced unresectable or metastatic HER2‑negative gastric or gastro-oesophageal junction adenocarcinoma in adults whose tumours express PD‑L1 with a combined positive score (CPS) of 1 or more. Because HER2‑negative locally advanced unresectable or metastatic gastro-oesophageal junction adenocarcinoma is now covered by the new recommendation in TA997, this indication has been removed from the recommendation in this guidance.
ISBN: 978-1-4731-6479-6